Pre-existing isoniazid resistance, but not the genotype of Mycobacterium Tuberculosis drives rifampicin resistance codon preference in vitro

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Bergval, Indra ^a   Kwok, Brian ^a,d   Schuitema, Anja ^a   Kremer, Kristin ^b,e   van Soolingen, Dick ^b,c   Klatser, Paul ^a   Anthony, Richard ^a  

^a ROYAL TROPICAL INSTITUTE   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE; GUANINE; ISONIAZID; RIFAMPICIN; THYMINE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM MUTANT; CODON; CONTROLLED STUDY; GENOTYPE; IN VITRO STUDY; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MUTATION RATE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; RPOB GENE; SEQUENCE ANALYSIS; STRAIN DIFFERENCE; DRUG EFFECT; GENETICS; HUMAN;

MYCOBACTERIUM TUBERCULOSIS;

ANTI-BACTERIAL AGENTS; CODON; DRUG RESISTANCE, BACTERIAL; GENOTYPE; HUMANS; ISONIAZID; MUTATION RATE; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN;

EID: 84855319056     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029108     Document Type: Article

References (64)

1. Alland D, Whittam TS, Murray MB, Cave MD, Hazbon MH, et al. (2003) Modeling bacterial evolution with comparative-genome-based marker systems: application to Mycobacterium tuberculosis evolution and pathogenesis. J Bacteriol 185 (11): 3392-3399.
2. Bergval IL, Schuitema ARJ, Klatser PR, Anthony RM, (2009) Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance. J Antimicrob Chemother 64 (3): 515-523.
3. Smith NH, Dale J, Inwald J, Palmer S, Gordon SV, et al. (2003) The population structure of Mycobacterium bovis in Great Britain: Clonal expansion. Proc Natl Acad Sci U S A 100 (25): 15271-15275.
4. Ramaswamy S, Musser JM, (1998) Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: update. Tuber Lung Dis 79: 3-29.
5. Riska PF, Jacobs WR, Alland D, (2000) Molecular determinants of drug resistance in tuberculosis. Int J Tuberc Lung Dis 4: S4-S10.
6. Van Deun A, Martin A, Palomino JC, (2010) Diagnosis of drug-resistant tuberculosis: reliability and rapidity of detection. Int J Tuberc Lung Dis 14 (2): 131-140.
7. Van Rie A, Warren R, Mshanga I, Jordaan AM, van der Spuy GD, et al. (2000) Analysis for a limited number of gene codons can predict drug resistance of Mycobacterium tuberculosis in a high-incidence community. J Clin Microbiol 39: 636-641.
8. Heep M, Brandstatter B, Reiger U, Lehn N, Richter E, et al. (2001) Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates. J Clin Microbiol 39: 107-110.
9. Anthony RM, Schuitema ARJ, Bergval IL, Brown TJ, Oskam L, et al. (2005) Acquisition of rifabutin resistance by a rifampicin resistant mutant of Mycobacterium tuberculosis involves an unusual spectrum of mutations and elevated frequency. Ann Clin Microbiol Antimicrob 4: 9.
10. Huitric E, Werngren J, Juréen P, Hoffner S, (2006) Resistance levels and rpoB gene mutations among in vitro-selected rifampin-resistant Mycobacterium tuberculosis mutants. Antimicrob Agents Chemother 50 (8): 2860-2862.
11. Jenkins C, Bacon J, Allnutt J, Hatch KA, Bose A, et al. (2009) Enhanced heterogeneity of rpoB in Mycobacterium tuberculosis found at low pH. J Antimicrob Chemother 63 (6): 1118-1120.
12. Morlock GP, Plikaytis BB, Crawford JT, (2000) Characterization of Spontaneous, In Vitro-Selected, Rifampin-Resistant Mutants of Mycobacterium tuberculosis Strain H37Rv. Antimicrob Agents Chemother 44 (12): 3298-3301.
13. Werngren J, Hoffner SE, (2003) Drug-susceptible Mycobacterium tuberculosis Beijing genotype does not develop mutation-conferred resistance to rifampin at an elevated rate. J Clin Microbiol 4 pp. 1520-1524.
14. Jenkins C, Claxton AP, Shorten RJ, McHugh TD, Gillespie SH, (2005) Rifampicin resistance in tuberculosis outbreak, London, England. Emerg Infect Dis 11: 931-934.
15. Hazbon MH, Brimacombe M, Bobadilla del Valle M, et al. (2006) Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 50: 2640-2649.
16. Hillemann D, Kubica T, Rüsch-Gerdes S, Niemann S, (2005) Disequilibrium in distribution of resistance mutations among Mycobacterium tuberculosis Beijing and non-Beijing strains isolated from patients in Germany. Antimicrob Agents Chemother 49: 1229-1231.
17. Lipin MY, Stepanshina VN, Shemyakin IG, Shinnick TM, (2007) Association of specific mutations in katG, rpoB, rpsL and rrs genes with spoligotypes of multidrug-resistant Mycobacterium tuberculosis isolates in Russia. Clin Microbiol Infect 13: 620-626.
18. Rinder H, Dobner P, Feldmann K, Rifai M, Bretzel G, et al. (1997) Disequilibria in the distribution of rpoB alleles in rifampicin-resistant M. tuberculosis isolates from Germany and Sierra Leone. Microb Drug Resist 3: 195-197.
19. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, et al. (2006) The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312: 1944-1946.
20. Gagneux S, Burgos MV, DeRiemer K, Encisco A, Muñoz S, et al. (2006) Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog 2: e61.
21. Weinreich DM, Delaney NF, DePristo MA, Hartl DL, (2006) Darwinian evolution can follow only very few mutational paths to fitter proteins. Science 312: 111-114.
22. Billington OJ, McHugh TD, Gillespie SH, (1999) Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemother 43: 1866-1869.
23. Mariam DH, Mengistu Y, Hoffner SE, Andersson DI, (2004) Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis. Antimicrob Agents Chemother 48: 1289-1294.
24. Toungoussova OS, Caugant DA, Sandven P, Mariandyshev AO, Bjune G, (2004) Impact of drug resistance on fitness of Mycobacterium tuberculosis strains of the W-Beijing genotype. FEMS Immunol Med Microbiol 42 (3): 281-290.
25. Bergval IL, Vijzelaar RN, Dalla Costa ER, Schuitema AR, Oskam L, et al. (2008) Development of multiplex assay for rapid characterization of Mycobacterium tuberculosis. J Clin Microbiol 46: 689-699.
26. Yates F, (1934) Contingency Tables Involving Small Numbers and the χ2 Test. Supplement to the Journal of the Royal Statistical Society 1 (2): 217-235.
27. Tsolaki AG, Gagneux S, Pym AS, Goguet de la Salmoniere YO, Kreiswirth BN, et al. (2005) Genomic deletions classify the Beijing/W strains as a distinct genetic lineage of Mycobacterium tuberculosis. J Clin Microbiol 43 (7): 3185-3191.
28. Mokrousov I, Narvskaya O, Otten T, Vyazovaya A, Limeschenko E, et al. (2002) Phylogenetic reconstruction within Mycobacterium tuberculosis Beijing genotype in northwestern Russia. Res Microbiol 153: 629-637.
29. Kremer K, van-der-Werf MJ, Au BK, Anh DD, Kam KM, et al. (2009) Vaccine-induced immunity circumvented by typical Mycobacterium tuberculosis Beijing strains. Emerg Infect Dis 15 (2): 335-339.
30. David HL, (1970) Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 20: 810-814.
31. Martinez JL, Baquero F, Andersson DI, (2007) predicting antibiotic resistance. Nat Rev Microbiol 12 pp. 958-965.
32. Saunders NJ, Trivedi UH, Thomson ML, Doig C, Laurenson IF, et al. (2011) Deep resequencing of serial sputum isolates of Mycobacterium tuberculosis during therapeutic failure due to poor compliance reveals stepwise mutation of key resistance genes on an otherwise stable genetic background. J Infect 62 (3): 212-217.
33. Cohen T, Sommers B, Murray M, (2003) The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis 3: 13.
34. Pym AS, Saint-Joanis B, Cole ST, (2002) Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect Immun 70: 4955-4960.
35. Van Doorn HR, de Haas PE, Kremer K, Vandenbroucke-Grauls CM, Borgdorff MW, et al. (2006) Public health impact of isoniazid-resistant Mycobacterium tuberculosis strains with a mutation at amino-acid position 315 of katG: a decade of experience in The Netherlands. Clin Microbiol Infect 12 (8): 769-775.
36. Björkman J, Nagaev I, Berg OG, Hughes D, Andersson DI, (2000) Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 287: 1479-1482.
37. O'Sullivan DM, McHugh TD, Gillespie SH, (2010) Mapping the fitness of Mycobacterium tuberculosis strains: a complex picture. J Med Microbiol pp. 1533-1535.
38. Bergval IL, Klatser PR, Schuitema AR, Oskam L, Anthony RM, (2007) Specific mutations in the Mycobacterium tuberculosis rpoB gene are associated with increased dnaE2 expression. FEMS Microbiol Lett 275: 338-343.
39. Li Z, Kelley C, Collins F, Rouse D, Morris S, (1998) Expression of katG in Mycobacterium tuberculosis is associated with its growth and persistence in mice and guinea pigs. J Infect Dis 177: 1030-1035.
40. Van Soolingen D, de Haas PE, van Doorn HR, Kuijper E, Rinder H, et al. (2000) Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. J Infect Dis 182: 1788-1790.
41. Sander P, Springer B, Prammananan T, Sturmfels A, Kappler M, et al. (2002) Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob Agents Chemother 46 (5): 1204-1211.
42. Hershberg R, Lipatov M, Small PM, Sheffer H, Niemann S, et al. (2008) High functional diversity in Mycobacterium tuberculosis driven by genetic drift and human demography. PLoS Biol 6 (12): e311 doi:10.1371/journal.pbio.0060311.
43. Reed MB, Pichler VK, McIntosh F, Mattia A, Fallow A, et al. (2009) Major Mycobacterium tuberculosis lineages associate with patient country of origin. J Clin Microbiol 47 (4): 1119-1128.
44. Caws M, Thwaites G, Dunstan S, Hawn TR, Lan NTN, et al. (2008) The Influence of Host and Bacterial Genotype on the Development of Disseminated Disease with Mycobacterium tuberculosis. PLoS Pathog 4 (3): e1000034 doi:10.1371/journal.ppat.1000034.
45. Mariam SH, Werngren J, Aronsson J, Hoffner S, Andersson DI, (2011) Dynamics of Antibiotic Resistant Mycobacterium tuberculosis during Long-Term Infection and Antibiotic Treatment. PLoS ONE 6 (6): e21147 doi:10.1371/journal.pone.0021147.
46. Schulz zur Wiesch P, Engelstädter J, Bonhoeffer S, (2010) Compensation of fitness costs and reversibility of antibiotic resistance mutations. Antimicrob Agents Chemother 54 (5): 2085-2095.
47. Cohen T, Murray M, (2004) Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med 10 (10): 1117-1121.
48. Luciani F, Sisson SA, Jiang H, Francis AR, Tanaka MM, (2009) The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 106 (34): 14711-5.
49. Schürch AC, Kremer K, Kiers A, Daviena O, Boeree MJ, et al. (2010) The tempo and mode of molecular evolution of Mycobacterium tuberculosis at patient-to-patient scale. Infect Genet Evol 10 (1): 108-114.
50. Bifani P, Mathema B, Kurepina N, Shashkina E, Bertout J, et al. (2008) The evolution of drug resistance in Mycobacterium tuberculosis: from a mono-rifampinresistant cluster into increasingly multidrug-resistant variants in an HIV-seropositive population. J Infect Dis 198: 90-94.
51. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, et al. (2006) Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368 (9547): 1575-1580.
52. Ford CB, Lin PL, Chase MR, Shah RR, Iartchouk O, et al. (2011) Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet 43: 482-486.
53. Comas I, Gagneux S, (2009) The Past and Future of Tuberculosis Research. PLoS Pathog 5 (10): e1000600 doi:10.1371/journal.ppat.1000600.
54. Iwamoto T, Yoshida S, Suzuki K, Wada T, (2008) Population structure analysis of the Mycobacterium tuberculosis Beijing family indicates an association between certain sublineages and multidrug resistance. Antimicrob Agents Chemother 52 (10): 3805-3809.
55. Trindade S, Sousa A, Xavier KB, Dionisio F, Ferreira MG, et al. (2009) Positive Epistasis Drives the Acquisition of Multidrug Resistance. PLoS Genet 5 (7): e1000578 doi:10.1371/journal.pgen.1000578.
56. Baker L, Brown T, Maiden MC, Drobniewski F, (2004) Silent nucleotide polymorphisms and a phylogeny for Mycobacterium tuberculosis. Emerg Infect Dis 10: 1568-1577.
57. Filliol I, Motiwala AS, Cavatore M, Qi W, Hernando Hazbon M, et al. (2006) Global phylogeny of Mycobacterium tuberculosis based on single nucleotide polymorphism (SNP) analysis: insights into tuberculosis evolution, phylogenetic accuracy of other DNA fingerprinting systems, and recommendations for a minimal standard SNP set. J Bacteriol 188: 759-772.
58. Gagneux S, Small PM, (2007) Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis 7: 328-337.
59. Gutacker MM, Mathema B, Soini H, Shashkina E, Kreiswirth BN, et al. (2006) Single-nucleotide polymorphism-based population genetic analysis of Mycobacterium tuberculosis strains from 4 geographic sites. J Infect Dis 193: 121-128.
60. Kremer K, van Soolingen D, Frothingham R, Haas WH, Hermans PW, et al. (1999) Comparison of methods based on different molecular epidemiological markers for typing of Mycobacterium tuberculosis complex strains: interlaboratory study of discriminatory power and reproducibility. J Clin Microbiol 37 (8): 2607-2618.
61. Gibson AL, Huard RC, Gey van Pittius NC, Lazzarini LC, Driscoll J, et al. (2008) Application of sensitive and specific molecular methods to uncover global dissemination of the major RDRio Sublineage of the Latin American-Mediterranean Mycobacterium tuberculosis spoligotype family. J Clin Microbiol 46 (4): 1259-1267.
62. Brudey K, Driscoll JR, Rigouts L, Prodinger WM, Gori A, et al. (2006) Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol 6: 23.
63. Kremer K, Glynn JR, Lillebaek T, Niemann S, Kurepina N, et al. (2004) Definition of the Beijing/W lineage of Mycobacterium tuberculosis on the basis of genetic markers. J Clin Microbiol 42 (9): 4040-4049.
64. Luria SE, Delbrück M, (1943) Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28: 491-511.